Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,457 1,497 1,502 1,482 1,430 1,387
Vimpat 976 1,053 1,161 1,259 1,353 1,076 762
Neupro 314 325 339 349 307 265 231
Briviact 87 155 226 228 346 398 444
Keppra 778 750 696 655 602 560 511

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,292  4,463  4,605 
Revenue  4,530 4,566 4,718 4,852
Recurring EBIT 1,130  1,104 1,149 1,220
Recurring EBITDA 1,375  1,347 1,388 1,463
Net Profit   753 793 828 894
Core EPS (€) 4.82  4.62 4.82 5.18

 

UCB FY Consensus Product Sales Estimates (Median)

In € million 2017a 2018e 2019e 2020e  2021e  2022e  2023e
Cimzia 1,424 1,460 1,500 1,529 1,477 1,419 1,383
Vimpat 976 1,065 1,185 1,276 1,357 1,055 762
Neupro 314 325 335 343 307 249 220
Briviact 87 151 227 286 347 400 450
Keppra 778 750 696 650 607 565 523

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2017a 2018e 2019e 2020e 
Net Sales  4,182 4,304 4,500  4,651 
Revenue  4,530 4,570 4,747 4,884
Recurring EBIT 1,130  1,102 1,153 1,230
Recurring EBITDA  1,375 1,346 1,400 1,480
Net Profit  753  775 816 881
Core EPS (€)  4.82 4.62 4.88 5.20

Downloads:
UCB FY 2018 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 11 Sept, 2018



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.